Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia
- Study Title
- A Phase 1, Single Dose, Parallel Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TV-44749, Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use, in Chinese Patients with Schizophrenia
- Teva Identifier
- TV44749-PK-10188
- ClinicalTrials.gov Identifier
- NCT06253546
- Study Status
- Completed
- Trial Condition(s)
- Schizophrenia
- Interventions
- Drug: TV-44749
- Study Description
- The primary objective is to evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia.
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 64 Years
- Trial Duration
- 28 March 2024 - 12 June 2025
- Phase
- Phase 1
